Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Income from Continuing Operations (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Income from Continuing Operations for 4 consecutive years, with 3177661.0 as the latest value for Q4 2024.

  • Quarterly Income from Continuing Operations rose 36.84% to 3177661.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 13904584.0 through Dec 2024, up 10.34% year-over-year, with the annual reading at 20427683.0 for FY2025, 46.91% down from the prior year.
  • Income from Continuing Operations hit 3177661.0 in Q4 2024 for Pasithea Therapeutics, down from 2999834.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 630143.0 in Q4 2021 to a low of 5031264.0 in Q4 2023.
  • Historically, Income from Continuing Operations has averaged 2724649.81 across 4 years, with a median of 3221735.5 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 743.25% in 2022 and later skyrocketed 36.84% in 2024.
  • Year by year, Income from Continuing Operations stood at 630143.0 in 2021, then tumbled by 743.25% to 4053404.0 in 2022, then decreased by 24.12% to 5031264.0 in 2023, then surged by 36.84% to 3177661.0 in 2024.
  • Business Quant data shows Income from Continuing Operations for KTTA at 3177661.0 in Q4 2024, 2999834.0 in Q3 2024, and 3866249.0 in Q2 2024.